Cerus PE Ratio 2012-2025 | CERS
Current and historical p/e ratio for Cerus (CERS) from 2012 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cerus PE ratio as of February 05, 2026 is 0.00.
| Cerus PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-02-06 | 2.20 | 0.00 | |
| 2025-09-30 | 1.59 | $-0.08 | 0.00 |
| 2025-06-30 | 1.41 | $-0.10 | 0.00 |
| 2025-03-31 | 1.39 | $-0.10 | 0.00 |
| 2024-12-31 | 1.54 | $-0.11 | 0.00 |
| 2024-09-30 | 1.74 | $-0.11 | 0.00 |
| 2024-06-30 | 1.76 | $-0.13 | 0.00 |
| 2024-03-31 | 1.89 | $-0.17 | 0.00 |
| 2023-12-31 | 2.16 | $-0.21 | 0.00 |
| 2023-09-30 | 1.62 | $-0.28 | 0.00 |
| 2023-06-30 | 2.46 | $-0.29 | 0.00 |
| 2023-03-31 | 2.97 | $-0.27 | 0.00 |
| 2022-12-31 | 3.65 | $-0.25 | 0.00 |
| 2022-09-30 | 3.60 | $-0.22 | 0.00 |
| 2022-06-30 | 5.29 | $-0.24 | 0.00 |
| 2022-03-31 | 5.49 | $-0.28 | 0.00 |
| 2021-12-31 | 6.81 | $-0.31 | 0.00 |
| 2021-09-30 | 6.09 | $-0.35 | 0.00 |
| 2021-06-30 | 5.91 | $-0.36 | 0.00 |
| 2021-03-31 | 6.01 | $-0.36 | 0.00 |
| 2020-12-31 | 6.92 | $-0.36 | 0.00 |
| 2020-09-30 | 6.26 | $-0.39 | 0.00 |
| 2020-06-30 | 6.60 | $-0.44 | 0.00 |
| 2020-03-31 | 4.65 | $-0.48 | 0.00 |
| 2019-12-31 | 4.22 | $-0.52 | 0.00 |
| 2019-09-30 | 5.16 | $-0.52 | 0.00 |
| 2019-06-30 | 5.62 | $-0.50 | 0.00 |
| 2019-03-31 | 6.23 | $-0.47 | 0.00 |
| 2018-12-31 | 5.07 | $-0.44 | 0.00 |
| 2018-09-30 | 7.21 | $-0.42 | 0.00 |
| 2018-06-30 | 6.67 | $-0.43 | 0.00 |
| 2018-03-31 | 5.48 | $-0.49 | 0.00 |
| 2017-12-31 | 3.38 | $-0.56 | 0.00 |
| 2017-09-30 | 2.73 | $-0.59 | 0.00 |
| 2017-06-30 | 2.51 | $-0.61 | 0.00 |
| 2017-03-31 | 4.45 | $-0.63 | 0.00 |
| 2016-12-31 | 4.35 | $-0.62 | 0.00 |
| 2016-09-30 | 6.21 | $-0.64 | 0.00 |
| 2016-06-30 | 6.24 | $-0.67 | 0.00 |
| 2016-03-31 | 5.93 | $-0.66 | 0.00 |
| 2015-12-31 | 6.32 | $-0.66 | 0.00 |
| 2015-09-30 | 4.54 | $-0.76 | 0.00 |
| 2015-06-30 | 5.19 | $-0.74 | 0.00 |
| 2015-03-31 | 4.17 | $-0.73 | 0.00 |
| 2014-12-31 | 6.24 | $-0.68 | 0.00 |
| 2014-09-30 | 4.01 | $-0.53 | 0.00 |
| 2014-06-30 | 4.15 | $-0.67 | 0.00 |
| 2014-03-31 | 4.80 | $-0.60 | 0.00 |
| 2013-12-31 | 6.45 | $-0.65 | 0.00 |
| 2013-09-30 | 6.72 | $-0.62 | 0.00 |
| 2013-06-30 | 4.42 | $-0.41 | 0.00 |
| 2013-03-31 | 4.42 | $-0.42 | 0.00 |
| 2012-12-31 | 3.16 | $-0.42 | 0.00 |
| 2012-09-30 | 3.40 | $-0.51 | 0.00 |
| 2012-06-30 | 3.32 | $-0.38 | 0.00 |
| 2012-03-31 | 4.02 | $-0.41 | 0.00 |
| 2011-12-31 | 2.80 | $-0.35 | 0.00 |
| 2011-09-30 | 2.12 | $-0.25 | 0.00 |
| 2011-06-30 | 3.00 | $-0.40 | 0.00 |
| 2011-03-31 | 2.91 | $-0.41 | 0.00 |
| 2010-12-31 | 2.46 | $-0.43 | 0.00 |
| 2010-09-30 | 3.84 | $-0.50 | 0.00 |
| 2010-06-30 | 3.16 | $-0.56 | 0.00 |
| 2010-03-31 | 2.79 | $-0.61 | 0.00 |
| 2009-12-31 | 1.99 | $-0.71 | 0.00 |
| 2009-09-30 | 2.19 | $-0.78 | 0.00 |
| 2009-06-30 | 1.03 | $-0.89 | 0.00 |
| 2009-03-31 | 0.68 | $-0.98 | 0.00 |
| 2008-12-31 | 0.70 | $-0.91 | 0.00 |
| 2008-09-30 | 4.13 | $-1.07 | 0.00 |
| 2008-06-30 | 4.09 | $-1.09 | 0.00 |
| 2008-03-31 | 5.77 | $-1.37 | 0.00 |
| 2007-12-31 | 6.51 | $-1.42 | 0.00 |
| 2007-09-30 | 8.73 | $-0.96 | 0.00 |
| 2007-06-30 | 6.76 | $-0.73 | 0.00 |
| 2007-03-31 | 6.75 | $-0.35 | 0.00 |
| 2006-12-31 | 5.86 | $-0.18 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.411B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $189.676B | 21.18 |
| EssilorLuxottica (ESLOY) | France | $140.849B | 0.00 |
| Stryker (SYK) | United States | $138.598B | 26.59 |
| Medtronic (MDT) | Ireland | $131.983B | 18.29 |
| Boston Scientific (BSX) | United States | $115.097B | 25.46 |
| Medline (MDLN) | United States | $60.694B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.604B | 0.00 |
| ResMed (RMD) | United States | $38.903B | 25.98 |
| GE HealthCare Technologies (GEHC) | United States | $37.513B | 17.97 |
| Agilent Technologies (A) | United States | $36.753B | 23.23 |
| Koninklijke Philips (PHG) | Netherlands | $27.809B | 18.16 |
| Terumo (TRUMY) | Japan | $18.896B | 21.35 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.585B | 10.97 |
| Insulet (PODD) | United States | $17.105B | 53.09 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.943B | 0.00 |
| Baxter (BAX) | United States | $11.191B | 9.03 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.080B | 29.05 |
| Demant (WILYY) | Denmark | $6.521B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.301B | 13.10 |
| Envista Holdings (NVST) | United States | $4.063B | 20.59 |
| BillionToOne (BLLN) | United States | $3.897B | 0.00 |
| ICU Medical (ICUI) | United States | $3.694B | 23.45 |
| Prestige Consumer Healthcare (PBH) | United States | $3.152B | 14.63 |
| Haemonetics (HAE) | United States | $3.044B | 13.22 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.014B | 0.00 |
| Neogen (NEOG) | United States | $2.304B | 50.43 |
| Phibro Animal Health (PAHC) | United States | $2.027B | 17.86 |
| LeMaitre Vascular (LMAT) | United States | $1.973B | 39.72 |
| Perrigo (PRGO) | Ireland | $1.964B | 4.92 |
| QuidelOrtho (QDEL) | United States | $1.949B | 12.53 |
| AtriCure (ATRC) | United States | $1.800B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.466B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.466B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.421B | 20.57 |
| Green Thumb Industries (GTBIF) | United States | $1.417B | 62.09 |
| BioLife Solutions (BLFS) | United States | $1.060B | 314.57 |
| Capricor Therapeutics (CAPR) | United States | $1.053B | 0.00 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.959B | 0.00 |
| InMode (INMD) | Israel | $0.937B | 10.59 |
| Tilray Brands (TLRY) | Canada | $0.821B | 0.00 |
| Valneva SE (VALN) | France | $0.803B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.790B | 0.00 |
| Omeros (OMER) | United States | $0.761B | 0.00 |
| CeriBell (CBLL) | United States | $0.717B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.578B | 15.66 |
| Verano Holdings (VRNO) | United States | $0.447B | 0.00 |
| Brainsway (BWAY) | Israel | $0.410B | 69.77 |
| Canopy Growth (CGC) | Canada | $0.398B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.361B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.326B | 26.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Evolus (EOLS) | United States | $0.286B | 0.00 |
| Quanterix (QTRX) | United States | $0.275B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.234B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.219B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Utah Medical Products (UTMD) | United States | $0.201B | 18.06 |
| Organigram Global (OGI) | Canada | $0.200B | 0.00 |
| High Tide (HITI) | Canada | $0.200B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.196B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.191B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.188B | 55.17 |
| Sanara MedTech (SMTI) | United States | $0.178B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.175B | 0.00 |
| Accendra Health (ACH) | United States | $0.170B | 1.71 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.151B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.146B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.69 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.104B | 0.00 |
| Biote (BTMD) | United States | $0.097B | 4.24 |
| Exagen (XGN) | United States | $0.076B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 23.49 |
| Sharps Technology (STSS) | United States | $0.041B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 29.85 |
| Cytosorbents (CTSO) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| Veru (VERU) | United States | $0.036B | 0.00 |
| Modular Medical (MODD) | United States | $0.034B | 0.00 |
| United-Guardian (UG) | United States | $0.033B | 16.63 |
| Jin Medical (ZJYL) | China | $0.022B | 0.00 |
| Bonk (BNKK) | United States | $0.019B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| INLIF (INLF) | China | $0.010B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| ZeroStack (ZSTK) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |